VA will not add Alzheimer’s drug Aduhelm to its formulary
By
Alicia Lasek
Aug 12, 2021
The Department of Veterans Affairs has chosen not to include aducanumab (Aduhelm) in its national list of covered drugs, citing risk of adverse events and lack of evidence of positive impact on cognition,...
‘Awakenings’ in advanced dementia patients inspire search for a cause
By
Alicia Lasek
Aug 07, 2019
Scientists have begun a search for the cause of a phenomena where people with late-stage Alzheimer’s disease are very lucid near the end of life.
Slow buy-in: Only 3% of neurologists have written Aduhelm prescriptions so far
By
Alicia Lasek
Jul 15, 2021
Neurologists are very aware of Biogen’s newly approved Alzheimer’s drug, but few have prescribed it so far, a real-time study of the brand’s market launch has found.
Two new studies identify potential warning signs of cognitive decline in older adults
By
John Roszkowski
Oct 13, 2023
Older adults who show subtle decline on standard memory and cognitive tests may be at increased risk for developing mild cognitive impairment, a precursor to dementia, according to the results of a new...
Medicare’s plan to cover Alzheimer’s drugs hinges on patient data registries
By
Alicia Lasek
Jun 02, 2023
Medicare Part B will cover Alzheimer’s drugs with traditional FDA approval, CMS announced Thursday. Prescribing clinicians must participate in a patient data registry.